Evidence map›Paper›PMID 33959506›Full record

ReviewFrontiers in oncology2021

Circular RNAs and Hepatocellular Carcinoma: New Epigenetic Players With Diagnostic and Prognostic Roles.

Kedeerya Aishanjiang, Xin-Dong Wei, Yi Fu, Xinjie Lin, Yujie Ma, Jiamei Le, Qiuqin Han, Xuan Wang, Xiaoni Kong, Jinyang Gu and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Kedeerya AishanjiangShanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Department of Collaborative Innovation Center for Biomedicine, Shanghai, China.
Xin-Dong WeiDepartment of General Surgery, The 81st Hospital Affiliated to Nanjing University of Traditional Chinese Medicine, Nanjing, China.
Yi FuShanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Department of Collaborative Innovation Center for Biomedicine, Shanghai, China.
Xinjie LinShanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Department of Collaborative Innovation Center for Biomedicine, Shanghai, China.
Yujie MaShanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Department of Collaborative Innovation Center for Biomedicine, Shanghai, China.
Jiamei LeShanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Department of Collaborative Innovation Center for Biomedicine, Shanghai, China.
Qiuqin HanShanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Department of Collaborative Innovation Center for Biomedicine, Shanghai, China.
Xuan WangDepartment of General Surgery, The 81st Hospital Affiliated to Nanjing University of Traditional Chinese Medicine, Nanjing, China.
Xiaoni KongInstitute of Clinical Immunology, Department of Liver Diseases, Central Laboratory, ShuGuang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jinyang GuDepartment of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Hailong WuShanghai University of Medicine and Health Sciences Affiliated Zhoupu Hospital, Department of Collaborative Innovation Center for Biomedicine, Shanghai, China.
Shanghai University of Medicine and Health Sciences · CNNanjing University · CNShanghai Jiao Tong University · CNShanghai University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Due to the lack of potent diagnosis and prognosis biomarkers and effective therapeutic targets, the overall prognosis of survival is poor in HCC patients. Circular RNAs (circRNAs) are a class of novel endogenous non-coding RNAs with covalently closed loop structures and implicated in diverse physiological processes and pathological diseases. Recent studies have demonstrated the involvement of circRNAs in HCC diagnosis, prognosis, development, and drug resistance, suggesting that circRNAs may be a class of novel targets for improving HCC diagnosis, prognosis, and treatments. In fact, some artificial circRNAs have been engineered and showed their therapeutic potential in treating HCV infection and gastric cancer. In this review, we introduce the potential of circRNAs as biomarkers for HCC diagnosis and prognosis, as therapeutic targets for HCC treatments and discuss the challenges in circRNA research and chances of circRNA application.

Indexed as

biomarkers for diagnosis and prognosiscircular RNAsdrug resistancehepatocellular carcinomaoncogenic circRNAstumor suppressive circRNAs

Identifiers

PMID33959506
PMCPMC8093866
OpenAlexW3152885738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.